These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
420 related articles for article (PubMed ID: 26887520)
21. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced non-small cell lung cancer in Chinese population: A retrospective study. Xu Y; Zheng X; Bai X; Li P; Ma H; Wang J; Hu X; Chen M Oncotarget; 2017 Jul; 8(30):49084-49092. PubMed ID: 28467775 [TBL] [Abstract][Full Text] [Related]
22. A phase II study of cisplatin plus S-1 with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0501. Nogami N; Takigawa N; Hotta K; Segawa Y; Kato Y; Kozuki T; Oze I; Kishino D; Aoe K; Ueoka H; Kuyama S; Harita S; Okada T; Hosokawa S; Inoue K; Gemba K; Shibayama T; Tabata M; Takemoto M; Kanazawa S; Tanimoto M; Kiura K Lung Cancer; 2015 Feb; 87(2):141-7. PubMed ID: 25534129 [TBL] [Abstract][Full Text] [Related]
23. The predictive value of Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034 [TBL] [Abstract][Full Text] [Related]
24. Effect of Radiation Therapy Techniques on Outcome in N3-positive IIIB Non-small Cell Lung Cancer Treated with Concurrent Chemoradiotherapy. Noh JM; Kim JM; Ahn YC; Pyo H; Kim B; Oh D; Ju SG; Kim JS; Shin JS; Hong CS; Park H; Lee E Cancer Res Treat; 2016 Jan; 48(1):106-14. PubMed ID: 25687865 [TBL] [Abstract][Full Text] [Related]
25. [Initial outcome of induction chemotherapy with weekly paclitaxel followed by three-dimensional conformal radiotherapy and concurrent weekly paclitaxel for stage III non-small cell lung cancer]. Wang WH; Bao Y; Chen M; Zhang L; Li KX; Xu GC; Deng XW; Lu TX; Cui NJ Ai Zheng; 2006 Oct; 25(10):1279-83. PubMed ID: 17059776 [TBL] [Abstract][Full Text] [Related]
26. Phase I study of concurrent high-dose three-dimensional conformal radiotherapy with chemotherapy using cisplatin and vinorelbine for unresectable stage III non-small-cell lung cancer. Sekine I; Sumi M; Ito Y; Horinouchi H; Nokihara H; Yamamoto N; Kunitoh H; Ohe Y; Kubota K; Tamura T Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):953-9. PubMed ID: 21377282 [TBL] [Abstract][Full Text] [Related]
27. S-1 plus cisplatin with concurrent radiotherapy for locally advanced non-small cell lung cancer: a multi-institutional phase II trial (West Japan Thoracic Oncology Group 3706). Ichinose Y; Seto T; Sasaki T; Yamanaka T; Okamoto I; Takeda K; Tanaka M; Katakami N; Sawa T; Kudoh S; Saka H; Nishimura Y; Nakagawa K; Fukuoka M J Thorac Oncol; 2011 Dec; 6(12):2069-75. PubMed ID: 22052226 [TBL] [Abstract][Full Text] [Related]
28. The combination of cisplatin and vinorelbine with concurrent thoracic radiation therapy for locally advanced stage IIIA or IIIB non-small-cell lung cancer. Hirose T; Mizutani Y; Ohmori T; Ishida H; Hosaka T; Ando K; Shirai T; Okuda K; Ohnishi T; Horichi N; Kubota H; Adachi M Cancer Chemother Pharmacol; 2006 Sep; 58(3):361-7. PubMed ID: 16331494 [TBL] [Abstract][Full Text] [Related]
29. Full-dose cisplatin and oral vinorelbine concomitant with radiotherapy in unresectable stage III non-small cell lung cancer: a multi-center phase II study. Juan O; Sánchez-Hernández A; Vázquez S; Casal J; Firvida JL; Aparisi F; Muñoz J; García-Sánchez J; Gironés R; Lázaro M; Giner V Anticancer Res; 2014 Apr; 34(4):1959-66. PubMed ID: 24692732 [TBL] [Abstract][Full Text] [Related]
30. Definitive chemoradiotherapy in Stage III nonsmall cell lung cancer: Turkey experience. Yilmaz U; Yılmaz U; Yasar Z; Kıraklı EK; Ulger S; Ozdogan Y; Demirci NY; Erol S; Ozdogan I; Sahin B; Koksal D; Akcay C J Cancer Res Ther; 2016; 12(1):334-9. PubMed ID: 27072260 [TBL] [Abstract][Full Text] [Related]
31. Radical radiotherapy or chemoradiotherapy for inoperable, locally advanced, non-small cell lung cancer: Analysis of patient profile, treatment approaches, and outcomes for 213 patients at a tertiary cancer center. Shrimali RK; Nallathambi C; Saha A; Das A; Prasath S; Mahata A; Arun B; Mallick I; Achari R; Dabkara D; Thambudorai R; Chatterjee S Indian J Cancer; 2018; 55(2):125-133. PubMed ID: 30604722 [TBL] [Abstract][Full Text] [Related]
32. Phase II trial of combined modality therapy with concurrent topotecan plus radiotherapy followed by consolidation chemotherapy for unresectable stage III and selected stage IV non-small-lung cancer. Seung SK; Ross HJ Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):802-9. PubMed ID: 18762390 [TBL] [Abstract][Full Text] [Related]
33. Phase I study of concurrent chemoradiation with pemetrexed and cisplatin followed by consolidation pemetrexed for patients with unresectable stage III non-small cell lung cancer. Cardenal F; Arnaiz MD; Morán T; Jové J; Nadal E; Porta R; Solé JM; Brao I; Palmero R; Fuentes R; Núñez I; Caveda E; Cassinello A Lung Cancer; 2011 Oct; 74(1):69-74. PubMed ID: 21353323 [TBL] [Abstract][Full Text] [Related]
34. Long-term survival of locally advanced stage III non-small cell lung cancer patients treated with chemoradiotherapy and perspectives for the treatment with immunotherapy. Vrankar M; Stanic K Radiol Oncol; 2018 Feb; 52(3):281-288. PubMed ID: 30210037 [TBL] [Abstract][Full Text] [Related]
35. Final results from a Phase II study of pemetrexed and cisplatin with concurrent thoracic radiation after Pem-Cis induction in patients with unresectable locally advanced non-squamous non-small cell lung cancer (NSCLC). Garrido P; Engel-Riedel W; Serke M; Giraud P; Ricardi U; Vallejo C; Visseren-Grul C; Ameryckx S; Soldatenkova V; Chouaki N; Novello S Lung Cancer; 2015 May; 88(2):160-6. PubMed ID: 25758556 [TBL] [Abstract][Full Text] [Related]
36. Phase II trial of recombinant human endostatin in combination with concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer. Bao Y; Peng F; Zhou QC; Yu ZH; Li JC; Cheng ZB; Chen L; Hu X; Chen YY; Wang J; Wang Y; Ma HL; Xu ZM; Lu RB; Deng XW; Chen M Radiother Oncol; 2015 Feb; 114(2):161-6. PubMed ID: 25497558 [TBL] [Abstract][Full Text] [Related]
37. Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer. Mayahara H; Uehara K; Harada A; Kitatani K; Yabuuchi T; Miyazaki S; Ishihara T; Kawaguchi H; Kubota H; Okada H; Ninomaru T; Shindo C; Hata A Radiat Oncol; 2022 Jan; 17(1):7. PubMed ID: 35033139 [TBL] [Abstract][Full Text] [Related]
38. Intensified high-dose chemoradiotherapy with induction chemotherapy in patients with locally advanced non-small-cell lung cancer-safety and toxicity results within a prospective trial. Pöttgen C; Eberhardt WE; Gauler T; Krbek T; Berkovic K; Jawad JA; Korfee S; Teschler H; Stamatis G; Stuschke M Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):809-15. PubMed ID: 19427744 [TBL] [Abstract][Full Text] [Related]
39. Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III non-small cell lung cancer. Wang L; Wu S; Ou G; Bi N; Li W; Ren H; Cao J; Liang J; Li J; Zhou Z; Lv J; Zhang X Lung Cancer; 2012 Jul; 77(1):89-96. PubMed ID: 22418243 [TBL] [Abstract][Full Text] [Related]
40. Randomized phase III trial of radiotherapy or chemoradiotherapy with topotecan and cisplatin in intermediate-risk cervical cancer patients after radical hysterectomy. Sun W; Wang T; Shi F; Wang J; Wang J; Hui B; Zhang Y; Lu J; Chen H; Liu Z BMC Cancer; 2015 May; 15():353. PubMed ID: 25935645 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]